Search Results

PharmaNest Inc. announces today that it will present, alongside its collaborators, seven abstracts at this year’s International Liver Congress - EASL in Milan, Italy, June 5-8, 2024.

Initial patient enrollment anticipated during first quarter of 2025

Grifols, one of the world’s leading producers of plasma-derived medicines, announced that Biotest, a Grifols Group company, forecasts approximately USD 1 billion in revenue from sales in the United States of its intravenous immunoglobulin Yimmugo® during the next seven years, following recent Food and Drug Administration approval to treat primary immunodeficiencies.

Endo International plc announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), is expanding its voluntary recall to include seven lots of Treprostinil Injection 20mg/20mL (1mg/mL) to the consumer level. The product is being recalled due to the potential for the presence of silicone particulates in the product.

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced that seven abstracts have been accepted for the 2024 ASCO Annual Meeting (ASCO), scheduled to take place May 31 – June 3, 2024, at McCormick Place Convention Center in Chicago, IL.

Talphera, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, announced as part of its commitment to operating with best practices in corporate governance, its Board of Directors has decided to reduce the size of the Board from ten to seven directors.

Ardelyx, Inc. announced between October 11, 2023 and October 29, 2023 the compensation committee of the company’s board of directors granted forty-seven new non-executive employees options to purchase an aggregate of 635,024 shares of the company’s common stock, and granted fifty-one new non-executive employees an aggregate of 591,900 Restricted Stock Units.

Esperion bagged broader-than-expected FDA labels for its cholesterol-busting drugs Friday, allowing the biotech to target seven times as many people in the U.S. compared to the old labels.